公开(公告)号：US12187721B2

公开(公告)日：2025-01-07

申请号：US17285997

申请日：2019-10-17

Applicant: Array BioPharma Inc.

Inventor： James Francis Blake ,  Mark Laurence Boys ,  Mark Joseph Chicarelli ,  Adam Wade Cook ,  Mohamed S. A. Elsayed ,  Jay Bradford Fell ,  John Peter Fischer ,  Ronald Jay Hinklin ,  Oren Teague Mcnulty ,  Macedonio J. Mejia ,  Martha E. Rodriguez ,  Christina Elizabeth Wong

IPC: C07D471/04 ,  C07D519/00

Abstract: Compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed

公开(公告)号：US20250000848A1

公开(公告)日：2025-01-02

申请号：US18823274

申请日：2024-09-03

Applicant: ASTRAZENECA AB ,  Array BioPharma, Inc.

Inventor： Nicola Frances BATEMAN ,  Paul Richard GELLERT ,  Kathryn Jane HILL

IPC: A61K31/4184 ,  A61K9/00 ,  A61K9/14 ,  A61K9/48 ,  A61K47/22 ,  A61K47/36 ,  C07D235/06

Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament, and to processes for the preparation of said compositions.

公开(公告)号：US12180207B2

公开(公告)日：2024-12-31

申请号：US17416117

申请日：2019-12-13

Applicant: ARRAY BIOPHARMA INC.

Inventor： James F. Blake ,  David A. Moreno ,  Li Ren ,  Tony P. Tang ,  Shane M. Walls

IPC: C07D471/04 ,  A61P35/00 ,  C07D519/00

Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Ring A, Ring B, Ring C, R1, R2, L, Y, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

公开(公告)号：US20240174666A1

公开(公告)日：2024-05-30

申请号：US18457795

申请日：2023-08-29

Applicant: Array BioPharma Inc.

Inventor： Ronald Jay Hinklin ,  Shelley Allen ,  Patrick Michael Doerner Barbour ,  Adam Wade Cook ,  Joshua Ryan Dahlke ,  John Joseph Gaudino ,  Ellen Ruth Laird ,  Oren Teague McNulty ,  Qian Zhao

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Provided herein are compounds of the Formula I:




and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.

公开(公告)号：US11932633B2

公开(公告)日：2024-03-19

申请号：US17053273

申请日：2019-05-06

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  James F. Blake ,  Mark Joseph Chicarelli ,  Jay Bradford Fell ,  John P. Fischer ,  Erik James Hicken ,  Pavel Savechenkov ,  Tony Tang ,  Guy P. A. Vigers ,  Henry J. Zecca

IPC: C07D413/06 ,  A61P35/00 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D413/14 ,  A61P35/00 ,  C07D413/06

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20240066029A1

公开(公告)日：2024-02-29

申请号：US18342314

申请日：2023-06-27

Applicant: Array BioPharma, Inc.

Inventor： Steven W. ANDREWS ,  Sean ARONOW ,  James F. Blake ,  Barbara J. BRANDHUBER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Oren T. MCNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Tony P. TANG ,  Li REN

IPC: A61K31/496 ,  C07D471/04 ,  A61P1/12 ,  A61P35/04 ,  C07D519/00 ,  A61P35/02 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551

CPC classification number: A61K31/496 ,  C07D471/04 ,  A61P1/12 ,  A61P35/04 ,  C07D519/00 ,  A61P35/02 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551

Abstract: Provided herein are compounds of the Formula I:




and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US11834453B2

公开(公告)日：2023-12-05

申请号：US17362580

申请日：2021-06-29

Applicant: Array BioPharma Inc.

Inventor： Mark Laurence Boys ,  Bryan Daniel Ellis ,  John Joseph Gaudino ,  Erik James Hicken ,  Ellen Ruth Laird ,  Nicholas Charles Lazzara ,  Bradley Jon Newhouse ,  Spencer Phillip Pajk

IPC: A61K31/519 ,  C07D487/04 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07D519/00

Abstract: This invention relates to compounds of Formula (I):




and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US11634409B2

公开(公告)日：2023-04-25

申请号：US17745346

申请日：2022-05-16

Applicant: Array BioPharma Inc.

Inventor： Patrick Michael Barbour ,  Katie Keaton Brown ,  Adam Wade Cook ,  Erik James Hicken ,  Dean Russell Kahn ,  Ellen Ruth Laird ,  Andrew Terrance Metcalf ,  David Austin Moreno ,  Bradley Jon Newhouse ,  Spencer Phillip Pajk ,  Brett Joseph Prigaro ,  Li Ren ,  Eugene Tarlton

IPC: C07D403/12 ,  C07D239/90 ,  C07D239/91 ,  A61K31/4184 ,  A61K45/06

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

公开(公告)号：US20230117328A1

公开(公告)日：2023-04-20

申请号：US17905536

申请日：2021-03-01

Applicant: Array BioPharma Inc.

Inventor： Karyn Sue BOUHANA ,  Jim Yuk-Fai WONG

IPC: A61K31/513 ,  A61K39/395 ,  A61K9/48 ,  A61P35/00

Abstract: This invention relates to a method of treating cancer by administering to a patient in need thereof, over a period of time, therapeutic agents that comprises Compound 1 or a pharmaceutically acceptable salt thereof on an intermittent dosing schedule alone or in combination with a PD-1 or PD-L1 inhibitor, to a patient in need thereof.

公开(公告)号：US20230090520A1

公开(公告)日：2023-03-23

申请号：US17530702

申请日：2021-11-19

Applicant: Array BioPharma, Inc.

Inventor： Steven W. ANDREWS ,  Sean ARONOW ,  James F. BLAKE ,  Barbara J. BRANDHUBER ,  Adam COOK ,  Julia HAAS ,  Yutong JIANG ,  Gabrielle R. KOLAKOWSKI ,  Elizabeth A. MCFADDIN ,  Megan L. MCKENNEY ,  Oren T. MCNULTY ,  Andrew T. METCALF ,  David A. MORENO ,  Tony P. TANG ,  Li REN

IPC: A61K31/496 ,  C07D471/04 ,  A61P1/12 ,  A61P35/04 ,  C07D519/00 ,  A61P35/02 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.